You have read all your free articles, to continue reading subscribe to read the rest of this content.
The US biotech company, focusing om messenger RNA therapeutics and vaccines, has announced plans to expand its commercial footprint in Europe across six additional countries. The announcement reinforces Moderna's commitment to Europe and vision as a global commercial enterprise, building on the rAlready a subscriber Login You have read all…
AstraZeneca will collaborate with ArcherDX, a genomic analysis company focused on precision oncology, to use personalized cancer monitoring to detect minimal residual disease (MRD) in patients with early-stage non-small cell lung cancer (NSCLC). ArcherDX’s personalized assay will be used in AstAlready a subscriber Login You have read all your free…
Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved in the European Union for the treatment of chronic kidney disease (CKD) in adults with and without type-2 diabetes. The approval by the European Commission is based on positive results from the DAPA-CKDAlready a subscriber Login You have read…
Oasmia Pharmaceutical has signed an agreement with Kazia Therapeutics, an Australian oncology-focused biotechnology company, to acquire exclusive global development rights for Cantrixil, a product candidate in development intended for the treatment of ovarian cancer. The agreement is the first inAlready a subscriber Login You have read all your free articles,…
